Herman Steen
Chief Executive Officer at BiOrion Technologies BV
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert A. H. van der Meer | M | 75 |
University of Groningen
| 35 years |
| Victor J. Nickolson | M | - |
BiOrion Technologies BV
 BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | - |
| Guus van Scharrenburg | M | 71 |
BiOrion Technologies BV
BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Martin Hessing | M | 63 |
BiOrion Technologies BV
BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | - |
| Klaas Poelstra | M | 60 |
BiOrion Technologies BV
BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | - |
| Tanja Cuppen | F | 55 |
University of Groningen
| 2 years |
| Martijn L. Schreurs | M | - |
University of Groningen
| 4 years |
| S. G. van der Lecq | M | 57 |
University of Groningen
| 1 years |
| Femke de Vries | F | 51 |
University of Groningen
| 4 years |
| Jakob de Haan | M | - |
University of Groningen
| 3 years |
| Rolf Veldman | M | - |
University of Groningen
| 4 years |
| Egbert Bierman | M | - |
University of Groningen
| 7 years |
| E. J. Kuipers | M | 65 |
University of Groningen
| 3 years |
| Marc Betgem | M | - |
University of Groningen
| 4 years |
| Roel de Vries | M | 56 |
University of Groningen
| 2 years |
| Mark Selles | M | - |
University of Groningen
| 4 years |
| Martijn H. J. van Maanen | M | - |
University of Groningen
| 3 years |
| Wouter Moerel | M | - |
University of Groningen
| 6 years |
| Reyer Zwiggelaar | M | - |
University of Groningen
| 4 years |
| Dirk W. Grijpma | M | - |
University of Groningen
| 3 years |
| Evert Homan | M | - |
University of Groningen
| 1 years |
| Hessel van Riel | M | 57 |
University of Groningen
| 2 years |
| Ton Huls | M | - |
University of Groningen
| 6 years |
| Dirkjan Masman | M | 73 |
University of Groningen
| 4 years |
| Harry Laan | M | - |
University of Groningen
| 3 years |
| David Kerstens | M | - |
University of Groningen
| 5 years |
| Lienke van Balderen | F | - |
University of Groningen
| 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Netherlands | 27 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Herman Steen
- Personal Network
